Abstract: Dementia is a devastating syndrome characterized by memory problems, confusion, and behavior changes that prevent people from performing everyday activities. It is the leading cause of dependency and disability amongst older people, resulting in a global economic cost of ~$1.3 trillion. Around 58 million people are currently afflicted by dementia worldwide, with Alzheimer’s disease (AD) causing most (60–70%) of these cases. Clinical trials for novel disease-modifying therapies for AD have repeatedly been unsuccessful over the past few decades, despite showing great promise in preclinical studies. However, some optimism has been restored in the last year due to the reported success of two novel biologic therapies in phase 3 clinical trials, lecanameb (Dyck et al., 2023) and donanemab (Sims et al., 2023), which were able to significantly slow disease progression in the prodromal phase of AD. Both treatments are monoclonal antibodies that target amyloid-β (Aβ), a protein that aggregates into the extracellular plaques that begin to form in the earliest stages of the disease. These new disease-modifying interventions highlight the key importance that early diagnosis will have if we are to reach the goal of turning AD into a treatable condition.